Dec 4 (Reuters) - Relmada Therapeutics' ( RLMD )

depression treatment is "unlikely" to meet the main goal of a

late-stage trial, it said on Wednesday, citing an independent

data monitoring committee's analysis.

The treatment, REL-1017, also known as esmethadone, was

being tested as an adjunctive for major depressive disorder

(MDD) to be used in combination with other approved

anti-depressants.

"Based on these results, Relmada will evaluate the full

dataset to determine next steps for the REL-1017 program," CEO

Sergio Traversa said in a statement.

Relmada had about $54.1 million in cash and its equivalents

as of Sept. 30.